A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Journal of Visualized Experiments · 2026
DOI: 10.3791/67979 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Blessed P Mbogo and 4 co-authors. Institution: Drug Discovery Lab, School of Science, Technology, Accessibility, Mathematics, and Public Health (STAMP), Gallaudet University. Major MEDLINE topics: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Proto-Oncogene Proteins, Protein Kinase Inhibitors. 53 references. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS, NLM NIH HHS.
Abstract (original language)
Polo-like Kinase 1 (PLK1) plays essential roles in the S, G2, and M phases of the cell cycle, and its overexpression is frequently observed in multiple cancers, including breast cancer, where it contributes to genomic instability and dysregulated apoptosis. Unlike conventional ATP-competitive inhibitors that target the kinase domain, selective inhibition of PLK1's polo-box domain (PBD) offers a promising strategy to disrupt protein-ligand interactions critical for mitotic progression, thereby triggering apoptosis in cancer cells. However, the high structural similarity between PLK1 and its homologs (PLK2 and PLK3), which are vital for neurological function and the stress response, respectively, necessitates exceptional selectivity to avoid off-target effects. To address this challenge, the protocol entails a bilingual (American Sign Language and English) computational workflow that integrates virtual screening, structural clustering, protein-ligand docking, binding affinity prediction, ADMET-S profiling, and quantum mechanical (QM) stability analysis. Starting from the SuperNatural 3.0 natural product database, compounds were filtered using breast cancer relevance and drug-likeness criteria, clustered to ensure chemical diversity, and evaluated their interactions with PLK1-, PLK2-, and PLK3-PBD structures. While virtual docking and in silico ADMET-S assessments cannot definitively confirm selectivity or mechanism of action, this study generates testable hypotheses and prioritizes a focused set of natural-product-derived candidates for future molecular dynamics simulations, biochemical validation, or experimental screening.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Drug Discovery Lab, School of Science, Technology, Accessibility, Mathematics, and Public Health (STAMP), Gallaudet University.
- Drug Discovery Lab, School of Science, Technology, Accessibility, Mathematics, and Public Health (STAMP), Gallaudet University; University of Connecticut.
- Drug Discovery Lab, School of Science, Technology, Accessibility, Mathematics, and Public Health (STAMP), Gallaudet University; tugba.kucukkal@gallaudet.edu.
Funding
- NIGMS NIH HHS
- NLM NIH HHS
Cite
APA
Mbogo, B. P., Fernsebner, S. R., Lawal, M. M., Lundberg, D. J., & Kucukkal, T. G. (2026). A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English. Journal of Visualized Experiments. https://doi.org/10.3791/67979
Vancouver
Mbogo BP, Fernsebner SR, Lawal MM, Lundberg DJ, Kucukkal TG. A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English. Journal of Visualized Experiments. 2026. doi:10.3791/67979
BibTeX
@article{Mbogo2026,
author = {Mbogo, Blessed P and Fernsebner, Samantha R and Lawal, Monsurat M and Lundberg, Daniel J and Kucukkal, Tugba G},
title = {A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/67979}
}
EUVIMED